Neurotensin Receptor
Neurotensin is a 13-amino acids peptide that is produced from a single precursor, pre-pro-neurotensin, which gives rise to both NTS and the related peptide neuromedin N. Neurotensin (NTS) is a tridecapeptide that acts as neurotransmitter or neuromodulator in the central nervous system (CNS), which has been related to CNS physiology and pathology, such as potent hypothermia, opioid-independent analgesia, Parkinson’s disease and Schizophrenia; In the periphery, NTS as a local hormone, which has a detrimental effect by contributing to fat storage, obesity and metabolic disorders. Among the diverse biological effects of NTS is an ability to promote the growth of tissue, this effect not only indicates a role for NTS in the regulation of normal tissue growth, but also suggests that NTS could contributes to the growth of cancers. Neurotensin exerts its effects primarily through two seven-transmembrane G-protein-coupled receptors (GPCR), namely high-affinity neurotensin receptor1 (NTSR1) and low-affinity neurotensin receptor (NTSR2), as well as through NTSR3 (Sortilin 1), a single transmembrane domain sorting receptor. β-catenin translocates to nucleus and associates with transcription factor T cell factor (Tcf), the β-catenin/Tcf complex activates NTSR1 gene transcription through binding to the functional consensus DNA binding site for Tcf in the NTSR1 promoter, suggesting that the Wnt/APC/β-catenin signaling pathway is responsible for dysregulation of NTSR1 in colon cancer.
The NTSR2 receptor is a 410-amino acids protein, which shares approximately 64% homology with NTSR1. The NTSR3 (sortilin 1) receptor is unique among the NTSRs that it is a single transmembrane domain receptor of the Type Ι family, which is not specific for NTS and can bind a variety of ligands, such as lipoprotein lipase, receptor associated protein (RAP), pro-neurotrophins and sphingolipid activator protein(SAP). The mechanisms underlying NTSR3-induced cancer progression depend, in part, on soluble NTSR3(sNTSR3), which is released by shedding from the extracellular domain of NTSR3; soluble NTSR3 increases intracellular calcium concentrations and induces focal adhesion kinase (FAK)/Src-dependent activation of the inositol1,4,5-trisphosphate (IP3) kinase pathway in adenocarcinoma epithelial cells. There are many signal transduction pathways that mediate the main effects of NTS and they have been studied in different types of cancer, including non-small cell lung cancers (NSCLC), pancreatic adenocarcinomas, prostate cancers, hepatocellular carcinoma, colon tumors, breast cancers, and gliomas. Neurotensin participates in each step of cancer progression, from survival and growth to metastatic spread, with all these cellular events activated because of the abnormal expression of NTSRs.
References
1.Ouyang Q, et al. Clin Exp Pharmacol Physiol. 2017;44(8):841–846.
The NTSR2 receptor is a 410-amino acids protein, which shares approximately 64% homology with NTSR1. The NTSR3 (sortilin 1) receptor is unique among the NTSRs that it is a single transmembrane domain receptor of the Type Ι family, which is not specific for NTS and can bind a variety of ligands, such as lipoprotein lipase, receptor associated protein (RAP), pro-neurotrophins and sphingolipid activator protein(SAP). The mechanisms underlying NTSR3-induced cancer progression depend, in part, on soluble NTSR3(sNTSR3), which is released by shedding from the extracellular domain of NTSR3; soluble NTSR3 increases intracellular calcium concentrations and induces focal adhesion kinase (FAK)/Src-dependent activation of the inositol1,4,5-trisphosphate (IP3) kinase pathway in adenocarcinoma epithelial cells. There are many signal transduction pathways that mediate the main effects of NTS and they have been studied in different types of cancer, including non-small cell lung cancers (NSCLC), pancreatic adenocarcinomas, prostate cancers, hepatocellular carcinoma, colon tumors, breast cancers, and gliomas. Neurotensin participates in each step of cancer progression, from survival and growth to metastatic spread, with all these cellular events activated because of the abnormal expression of NTSRs.
References
1.Ouyang Q, et al. Clin Exp Pharmacol Physiol. 2017;44(8):841–846.
GPCR/G Protein
ACAT(3)
Angiotensin Receptor(27)
Antibacterial(471)
Bombesin Receptor(11)
Bradykinin Receptor(18)
Calcium Channel(137)
cAMP(9)
Cannabinoid Receptor(69)
CaSR(17)
CGRP Receptor(14)
Chemokine Receptor(104)
Cholecystokinin Receptor(17)
CRF Receptor(13)
Dopamine Receptor(145)
Endothelin Receptor(20)
FFAR(5)
Galanin Receptor(1)
GHSR(16)
Glucagon Receptor(36)
GPCR19(7)
GPR119(3)
Hedgehog (Hh)(27)
Histamine Receptor(110)
Imidazoline Receptor(1)
Leukotriene Receptor(9)
LHR(1)
LPA Receptor(12)
Lysophospholipid Receptor(13)
mAChR(25)
MCHR(6)
Melanocortin Receptor(22)
Melatonin Receptor(5)
mGluR(11)
Motilin Receptor(4)
Neurokinin Receptor(34)
Neuropeptide Y Receptor(36)
Neurotensin Receptor(8)
Orexin Receptor(14)
Other Targets(3)
OXTR(2)
P2Y Receptor(8)
PAR(24)
Platelet-activating Factor Receptor(2)
Prostaglandin Receptor(60)
PTH Receptor(1)
S1P Receptor(22)
SGLT(22)
Somatostatin Receptor(11)
Urotensin Receptor(4)
Vasopressin Receptor(16)
Neurotensin Receptor
-
JMV 449
catalog no : M30661
cas no: 139026-66-7
Potent, metabolically stable neurotensin receptor agonist peptide (IC50 = 0.15 nM for inhibition of [125I]-NT binding to neonatal mouse brain; EC50 = 1.9 nM for contraction of guinea pig ileum). Produces long-lasting hypothermic, neuroprotective and analgesic effects in mice following central administration in vivo. -
Neurotensin(8-13)
catalog no : M30135
cas no: 60482-95-3
Neurotensin (8-13) is a neuropeptide that corresponds to the C-terminal residues 8-13 of neurotensin that binds to rat synaptic membranes with a Ki value of 13 nM.1 It induces contraction of guinea pig ileum (EC50 = 25 nM) and induces contraction of rat fundus equipotently to full length neurotensin (EC50s = 1.29 and 1.58 nM, respectively). -
SB 611812
catalog no : M27706
cas no: 345892-71-9
SB 611812 is an antagonist of urotensin-II (UT) and can be used in studies about the treatment of cardiovascular disease. -
SBI-553
catalog no : M23841
cas no: 1849603-72-0
SBI-553 is an effective and brain penetrant NTR1 allosteric modulator (EC50: 0.34 μM). -
SR 142948
catalog no : M23837
cas no: 184162-64-9
SR 142948 is a neurotensin (NT) receptor antagonist.